Crossmark

First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum

Crossref DOI link: https://doi.org/10.1007/s00259-024-06641-w

Published Online: 2024-03-07

Published Print: 2024-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fricke, Julia

Westerbergh, Frida

McDougall, Lisa

Favaretto, Chiara

Christ, Emanuel

Nicolas, Guillaume P.

Geistlich, Susanne

Borgna, Francesca

Fani, Melpomeni

Bernhardt, Peter

van der Meulen, Nicholas P.

Müller, Cristina

Schibli, Roger

Wild, Damian http://orcid.org/0000-0002-8135-5350
Funding

Funding for this research was provided by:

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (32003B_205070)

University of Basel
License Information

Text and Data Mining valid from 2024-03-07

Version of Record valid from 2024-03-07
More Information

Article History

Received: 21 December 2023

Accepted: 31 January 2024

First Online: 7 March 2024

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Northwest and Central Switzerland (01.03.2022, No: 2022-00162).

: Informed consent was obtained from the patient before the inclusion into the study. The patient gave written informed consent to anonymously use their clinical and imaging data for publication.

: CM, RS, NM, MF and DW are listed as inventors on patent application US 2023/0165981, which contains [<sup>161</sup>Tb]Tb-DOTA-LM3. PB is a co-founder of Theravision AB.

: This study is registered with ClinicalTrials.gov (NCT05359146).

Document is current

Any future updates will be listed below